Using 3D ultrasound to detect ovulation
Three Dimensional Ultrasonographic Detection of Human Ovulation and Anovulation
This study is testing if 3D ultrasound can better detect ovulation compared to 2D ultrasound in healthy women to help improve infertility treatments.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | University of Saskatchewan Academic / other |
| Locations | 1 site (Saskatoon, Saskatchewan) |
| Trial ID | NCT06433453 on ClinicalTrials.gov |
What this trial studies
This research compares the effectiveness of 2D and 3D ultrasonography in diagnosing ovulation and anovulation in healthy women. Thirty participants will receive indomethacin to induce anovulation, followed by daily ultrasound scans and hormonal tests to monitor changes. A second group of participants from a previous study will serve as a control to evaluate the differences in ultrasound features between ovulatory and anovulatory conditions. The goal is to determine if 3D ultrasonography offers improved assessment for infertility treatments.
Who should consider this trial
Good fit: Ideal candidates are healthy biological females with regular menstrual cycles.
Not a fit: Patients with a history of infertility or reproductive health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of ovulation assessments, leading to better infertility treatment outcomes.
How similar studies have performed: Previous studies have explored similar methodologies, but this specific comparison of 2D and 3D ultrasound in ovulation detection is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy biological females * Regular menstrual cycles (21-35 days) Exclusion Criteria: * BMI \<18 or \>30 * Pregnancy * Breastfeeding mothers * History of infertility * History of hysterectomy or oophorectomy * Reproductive health issues that can interfere with study outcomes * Smoking * Not on any hormonal medication that affects reproduction (including hormonal contraception) * History of metabolic syndrome or untreated thyroid disease * Contra-indication to non-steroidal anti-inflammatory drug (NSAID) use. These include: * Gastric ulcers or gastro-intestinal bleeding * History of myocardial infarction or a coronary artery bypass * Cerebrovascular disease * Hypertension * Chronic or acute renal failure * Severe liver disease * Nasal polyp syndrome
Where this trial is running
Saskatoon, Saskatchewan
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Saskatchewan — Saskatoon, Saskatchewan, Canada (Recruiting)
Study contacts
- Principal investigator: Angela R Baerwald, PhD,MD,CCFP — University of Saskatchewan
- Study coordinator: Angela R Baerwald, PhD,MD,CCFP
- Email: angela.baerwald@usask.ca
- Phone: 306-555-4200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.